2021
DOI: 10.1016/j.jpba.2021.114330
|View full text |Cite
|
Sign up to set email alerts
|

Multi-attribute method performance profile for quality control of monoclonal antibody therapeutics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
21
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
4
1
1

Relationship

0
6

Authors

Journals

citations
Cited by 24 publications
(21 citation statements)
references
References 26 publications
0
21
0
Order By: Relevance
“…Trypsin is the most widely used enzyme for RPM-MAM using high-resolution MS in the literature thus far. [9][10][11][12][13][14][15] The time-course evaluation of trypsin digestion highlights the need of a desalting step for sample preparation in order to achieve fast and complete digestion (Figure 1). 10,15,20 The desalting step in a trypsin digestion may bring another source of variations and prevent high-throughput MAM testing and the full automation of MAM due to the many challenges of implementing desalting steps in an automated workflow.…”
Section: Sample Preparation and Digestion Strategies Of Mammentioning
confidence: 99%
See 4 more Smart Citations
“…Trypsin is the most widely used enzyme for RPM-MAM using high-resolution MS in the literature thus far. [9][10][11][12][13][14][15] The time-course evaluation of trypsin digestion highlights the need of a desalting step for sample preparation in order to achieve fast and complete digestion (Figure 1). 10,15,20 The desalting step in a trypsin digestion may bring another source of variations and prevent high-throughput MAM testing and the full automation of MAM due to the many challenges of implementing desalting steps in an automated workflow.…”
Section: Sample Preparation and Digestion Strategies Of Mammentioning
confidence: 99%
“…[2][3][6][7][8] As such, the multi-attribute method (MAM), including PQA monitoring and purity testing through new peak detection (NPD), serve as an orthogonal method and could eventually replace several traditional HPLC and CE-based assays currently used for characterization and release of biopharmaceuticals. [9][10][11][12][13][14][15][16][17][18][19] One of the challenges for the implementation of MAM in Good Manufacturing Practice (GMP)/ quality control (QC) areas is the streamlined sample preparation, which enables robust highthroughput testing while controlling assay variability. Reduced peptide mapping-based MAM (RPM-MAM) involves enzymatic digestion of proteins into peptides for MS detection.…”
Section: Introductionmentioning
confidence: 99%
See 3 more Smart Citations